License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2021
Beam Therapeutics Inc. (Beam) | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment to collaborators				$ 50,000,000
Beam Therapeutics Inc. (Beam) | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Developmental and commercial milestone payments and royalties on licensed products payable					$ 65,000,000
Beam Therapeutics Inc. (Beam) | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Beneficial ownership percentage held by a member of board of directors					10.00%
Harvard College
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregated consideration paid	$ 12,000,000
Common stock shares issued	9,000,000
Payment to collaborators	$ 3,000,000
Share issue price	$ 4
Maximum period expected to achieve for success payments	12 years
Harvard College | Long-term Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Estimated fair value of success payment liability		$ 1,600,000	$ 2,000,000
Harvard College | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Expense in connection with change in estimated fair value of success payment liability		$ (300,000)	$ (12,200,000)	$ 2,400,000
Harvard College | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cobalt success payment	$ 175,000,000